Table 4.
Clinical Outcomes According to Stress Tests Results and Presence of CMD
|
Group 1 INOCA(−)/CMD(−) |
Group 2 INOCA(−)/CMD(+) |
Group 3 INOCA(+)/CMD(−) |
Group 4 INOCA(+)/CMD(+) |
P value | |
|---|---|---|---|---|---|
| Total (N=287) | 116 (40.4%) | 90 (31.4%) | 41 (14.3%) | 40 (13.9%) | |
| All‐cause death | 3 (3.5%) | 8 (14.0%) | 2 (5.3%) | 2 (18.8%) | 0.151 |
| Cardiac death | 1 (1.3%) | 7 (11.6%) | 2 (5.3%) | 1 (12.5%) | 0.056 |
| Target‐vessel MI | 1 (1.4%) | 0 (0%) | 2 (5.3%) | 0 (0%) | 0.037 |
| Any revascularization | 4 (4.0%) | 9 (10.7%) | 1 (2.4%) | 6 (19.2%) | 0.025 |
| TVR* | 2 (2.3%) | 6 (6.8%) | 1 (2.4%) | 5 (17.1%) | 0.024 |
| Non‐TVR | 2 (1.8%) | 3 (4.1%) | 0 (0%) | 1 (2.6%) | 0.636 |
| MACE † | 7 (7.4%) | 15 (21.3%) | 3 (7.7%) | 8 (34.4%) | 0.007 |
Data expressed as number of events (%). The cumulative incidence of clinical outcomes is presented as Kaplan–Meier estimates during the median follow‐up of 1194.0 days (Q1–Q3, 730.0–1826.0 days). The P values were log‐rank P value in survival analysis. CMD indicates coronary microvascular disease; INOCA, ischemia with nonobstructive coronary arteries; MACE, major adverse cardiac event; MI, myocardial infarction; and TVR, target vessel revascularization.
Defined as clinically driven revascularization of the target vessel by means of coronary bypass grafting or percutaneous coronary intervention.
Defined as cardiac death, acute myocardial infarction not clearly attributable to a nontarget vessel, and clinically driven revascularization of the target vessel by means of coronary bypass grafting or percutaneous coronary intervention.